광주과학기술원;GENOME AND COMPANY;주식회사 지놈앤컴퍼니;GWANGJU INSTITUTE OF SCIENCE AND TECHNOLOGY
发明人:
PARK, Hansoo,박한수,SOHN, Jinyoung,손진영,KIM, Yun Yeon,김윤연,KIM, Sang Gyun,김상균,LEE, Suro,이수노,PARK, Shinyoung,박신영,LEE, Eun Ju,이은주,YEON, Jae-Sung,연제성,JEON, Hye Hee,전혜희,KIM, Wonduck,김원덕,CHUNG, Joo-Yeon,정주연,JEO
申请号：
KRKR2019/005518
公开号：
WO2019/216649A1
申请日:
2019.05.08
申请国别(地区):
KR
年份:
2019
代理人:
摘要：
The present invention relates to a novel Bifidobacterium bifidum MG731 strain and a composition for prophylaxis or therapy of cancer, which comprises same. Specifically, the Bifidobacterium bifidum MG731 strain of the present invention exhibits effects of inhibiting cancer cell proliferation, decreasing cancer cell motility, suppressing angiogenesis, and increasing anticancer immune responses as well as downregulating the expression of inflammatory factors, thereby preventing or treating cancer or inflammatory diseases. In addition, when used in combination with a chemotherapeutic agent or immunotherapeutic agent, the Bifidobacterium bifidum MG731 strain of the present invention exhibits a better anticancer effect. Further, the present invention relates to a novel Lactococcus lactis GEN3033 strain and a composition for prophylaxis or therapy of cancer, which comprises same. Specifically, the Lactococcus lactis GEN3033 strain of the present invention exhibits the effect of directly inhibiting cancer cell proliferation and enhancing immunity, thereby preventing or treating cancer. Particularly, the strain has an excellent anticancer effect by secreting metabolites having inhibitory activity against cancer while being established in the gut. In addition, when used in combination with a chemotherapeutic agent or an immunotherapeutic agent, the Lactococcus lactis GEN3033 of the present invention exhibits a better anticancer effect.La présente invention concerne une nouvelle souche de Bifidobacterium bifidum MG731 et une composition destinée à la prophylaxie ou au traitement du cancer, qui comprend celle-ci. Spécifiquement, la souche de Bifidobacterium bifidum MG731 de la présente invention présente des effets d'inhibition de la prolifération des cellules cancéreuses, de diminution de la motilité des cellules cancéreuses, de suppression de l'angiogenèse, et d'augmentation des réponses immunitaires anticancéreuses ainsi que la régulation à la baisse de l'expression de fact
